Get the Stockscreener App
14.49
6.27%
-0.9645
Nurix Therapeutics Inc stock is traded at $14.49, with a volume of 436.82K.
It is down -6.27% in the last 24 hours and down -23.58% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$15.45
Open:
$15.41
24h Volume:
436.82K
Relative Volume:
0.59
Market Cap:
$1.12B
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-5.0123
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
-14.10%
1M Performance:
-23.58%
6M Performance:
-41.75%
1Y Performance:
+6.80%
1-Day Range:
$14.40
$15.51
1-Week Range:
$14.39
$17.29
52-Week Range:
$11.90
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
14.50 | 1.12B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.63 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.61 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
635.59 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.60 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.72 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $31.81 Average Price Target from Analysts - MarketBeat
(NRIX) Trading Report - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by ARK Investment Management LLC - MarketBeat
Oversold Conditions For Nurix Therapeutics (NRIX) - Nasdaq
Allspring Global Investments Holdings LLC Decreases Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Allspring Global Investments Holdings LLC Reduces Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Analysts Predict How High Nurix Therapeutics Inc (NRIX) Will Go. - Stocks Register
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha
Nurix Therapeutics: A Story To Monitor (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics (NRIX) to Release Quarterly Earnings on Thursday - Defense World
Sumitomo Mitsui Trust Group Inc. Has $14.87 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NRIX) Projected to Post Earnings on Thursday - MarketBeat
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Strategic Equity Package: Nurix Therapeutics Secures Top Talent with $8.2M Employee Stock Awards - StockTitan
Sumitomo Mitsui Trust Group Inc. Raises Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NRIX) Projected to Post Quarterly Earnings on Thursday - Defense World
Nurix Therapeutics Inc [NRIX] Investment Appeal on the Rise - Knox Daily
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update - br.ADVFN.com
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update - br.ADVFN.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $31.12 Consensus Price Target from Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat
There is no doubt that Nurix Therapeutics Inc (NRIX) ticks all the boxes. - SETE News
Trading Day Triumph: Nurix Therapeutics Inc (NRIX) Ends at 18.59, a -1.90 Surge/Plunge - The Dwinnex
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Nurix Therapeutics (NASDAQ:NRIX) Stock - Defense World
NRIX (Nurix Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
HC Wainwright Expects Lower Earnings for Nurix Therapeutics - MarketBeat
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
Nurix Therapeutics Officer Sells Shares - TradingView
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 2,811 Shares - MarketBeat
Balanced Outlook on Nurix Therapeutics: Hold Rating Amidst Promising Trials and Uncertainties - TipRanks
Nurix Therapeutics (NRIX) – Research Analysts’ Weekly Ratings Changes - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,690 Shares - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $27.00 at Royal Bank of Canada - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Given New $36.00 Price Target at Stifel Nicolaus - MarketBeat
Nurix Therapeutics' SWOT analysis: protein degrader stock's potential - MSN
Nurix Therapeutics (NASDAQ:NRIX) Price Target Raised to $36.00 at HC Wainwright - MarketBeat
Needham & Company LLC Cuts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat
JPMorgan Chase & Co. Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
SG Americas Securities LLC Buys 7,141 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Q1 EPS Estimate for Nurix Therapeutics Reduced by Analyst - Defense World
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nurix Therapeutics Inc Stock (NRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Jan 31 '25 |
Sale |
19.95 |
5,760 |
114,934 |
32,538 |
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):